Home/Filings/4/0001562180-25-000916
4//SEC Filing

Burke Steven Keith 4

Accession 0001562180-25-000916

CIK 0001517022other

Filed

Feb 3, 7:00 PM ET

Accepted

Feb 4, 5:53 PM ET

Size

11.7 KB

Accession

0001562180-25-000916

Insider Transaction Report

Form 4
Period: 2025-01-31
Burke Steven Keith
SVP, Chief Medical Officer
Transactions
  • Sale

    Common Stock

    2025-02-03$2.10/sh27,236$57,196816,234 total
  • Award

    Stock Option (Right to buy)

    2025-01-31+292,300292,300 total
    Exercise: $2.24Exp: 2035-01-31Common Stock (292,300 underlying)
  • Sale

    Common Stock

    2025-02-03$2.10/sh23,270$48,867843,470 total
  • Award

    Common Stock

    2025-01-31+194,900866,740 total
Footnotes (6)
  • [F1]The restricted stock units were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date.
  • [F2]Includes 1,500 shares of the Issuer's common stock purchased on June 28, 2024 and 1,500 shares of the Issuer's common stock purchased on December 31, 2024, each under the Issuer's Amended and Restated 2014 Employee Stock Purchase Plan.
  • [F3]This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2023.
  • [F4]This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 17, 2023.
  • [F5]This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2024.
  • [F6]The options were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.

Issuer

Akebia Therapeutics, Inc.

CIK 0001517022

Entity typeother

Related Parties

1
  • filerCIK 0001619834

Filing Metadata

Form type
4
Filed
Feb 3, 7:00 PM ET
Accepted
Feb 4, 5:53 PM ET
Size
11.7 KB